4D Molecular Therapeutics' Q3 revenue misses
4D Molecular Therapeutics reported Q3 revenue of $90,000, missing analyst expectations of $287,900. The net income also fell short at -$56.88 million compared to the expected -$56.20 million. The company has entered a strategic partnership with Otsuka, receiving $85 million upfront, which is expected to support its cash runway into the second half of 2028. The average analyst rating remains a 'buy' with a 12-month price target of $34.50, reflecting a potential upside of 69.6% from its recent closing price of $10.50.
)
Overview
- 4D Molecular Therapeutics Q3 revenue missed analyst expectations
- Net income for Q3 missed analyst estimates
- Company entered strategic partnership with Otsuka, receiving $85 mln upfront cash
Outlook
- 4DMT expects cash runway into 2H 2028, supported by Otsuka partnership and equity offering
- 4DMT expects interim data from AEROW Phase 1 trial by year-end 2025
Result Drivers
- Research and development expenses were $49.4 million for the third quarter of 2025, as compared to $38.5 million for the third quarter of 2024
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Miss $90,000 $287,900
Revenue (7
Analysts
)
Q3 Net Miss -$56.88 -$56.20
Income mln mln (4
Analysts
)
Q3 Slight -$61.19 -$61.60
Operatin Beat* mln mln (5
g Income Analysts
)
Q3 Basic -$1.01
EPS
Q3 $61.28
Operatin mln
g
Expenses
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 9 “strong buy” or “buy”, 2 “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for 4D Molecular Therapeutics Inc is $34.50, about 69.6% above its November 7 closing price of $10.50
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
